Incidence and determinants of antidepressant drug use in migraine patients

International Clinical Psychopharmacology

Volumn 18, Issue 6, 2003, Pages 331-339

  Rahimtoola, H ^a,b,e   Buurma, H ^a   Tijssen, C C ^c   Leufkens, H G ^a   Egberts, A C G ^a,d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b SIR Institute for Pharmacy Practice and Policy   (Netherlands)

^c CPRLab   (Netherlands)

^d GGZ Midden Brabant   (Netherlands)

^e Apotheek de Notekraker   (Netherlands)

Author keywords

Antidepressant; Ergotamine; Migraine; Sumatriptan; Therapeutic intensity

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIMIGRAINE AGENT; BENZODIAZEPINE DERIVATIVE; CLONIDINE; ERGOTAMINE; FLUNARIZINE; FLUOXETINE; FLUVOXAMINE; METHYSERGIDE; MIANSERIN; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NAFAZODONE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIZOTIFEN; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DRUG USE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PHARMACOEPIDEMIOLOGY; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; ANALGESICS; ANTIDEPRESSIVE AGENTS; DATABASES, FACTUAL; DRUG UTILIZATION; ERGOTAMINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NETHERLANDS; RETROSPECTIVE STUDIES; SUMATRIPTAN; VASOCONSTRICTOR AGENTS;

EID: 0842309257     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200311000-00004     Document Type: Article

References (37)

1. Anatomical Therapeutic Chemical (ATC) classification index. (1993). Oslo: WHO Collaborating Centre for Drug Statistics Methodology.
2. Bellantuono C, Mazzi MA, Tansella M, Rizzo R, Goldberg D (2002). The identification of depression and the coverage of antidepressant drug prescriptions in Italian general practice. J Affect Disord 72:53-59.
3. Birkenhaeger T, Moleman P, Nolen W (1995). Benzodiazepines for depression? A review of the literature. Int Clin Psychopharmacol 10:181-195.
4. Breslau N, Schultz LR, Stewart WF, Lipton RB, Lucia VC, Welch KM (2000). Headache and major depression: is the association specific to migraine? Neurology 54:308-313.
5. Breslau N (1998). Psychiatric comorbidity in migraine. Cephalalgia 18(suppl 22):56-61.
6. Breslau N, Davis GC, Andreski P (1991). Migraine, psychiatric disorders, and suicide attempts: an epidemiologic study of young adults. Psychiatry Res 41:11-23.
7. Devlen J (1994). Anxiety and depression in migraine. J R Soc Med 87:338-341.
8. Druss BG, Hoff RA, Rosenheck RA (2000). Under use of antidepressants in major depression: prevalence and correlates in a national sample of young adults. J Clin Psychiatry 61:234-237.
9. Edmeads J, Findlay H, Tugwell P, Pryse-Phillips W, Nelson RF, Murray TJ (1993). Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci 20:131-137.
10. Evers S, Gralow I, Bauer B, Suhr B, Buchheister A, Husstedt IW, et al. (1999). Sumatriptan and ergotamine overuse and drug induced headache: a clinicoepidemiologic study. Clin Neuropharm 22:201-206.
11. Fasmer OB (2001). The prevalence of migraine in patients with bipolar and unipolar affective disorders. Cephalalgia 21:894-899.
12. Furlong S, Pryse-Phillips W, Crowley M, Turner C (1996). Prescribing practices for the management of headache in Newfoundland and Labrador. Headache 36:542-546.
13. Gaist D (1999). Use and overuse of sumatriptan. Pharmacoepidemiological studies based on prescription register and interview data. Cephalagia 19:735-761.
14. Guillemn E, Pelissolo A, Lepine JP (1999), Mental disorders and migraine: epidemiologic studies. Encephale 25:436-442.
15. Herings RM, Bakker A, Stricker BH, Nap G (1992). Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health 46:136-140.
16. Joffe RT, Sokolov ST (1997). Co-administration of fluoxetine and sumatriptan: the Canadian experience. Acta Psychiatr Scand 95:551-552.
17. Joish VV, Cady P, Bennet D, Harris R (2000). An epidemiological case-control study of migraine and its associated comorbid conditions. Ann Epidemiol 10:460.
18. Juang KD, Wang SJ, Fuh JL, Lu SR, Su TP (2000). Comorbidity of depressive and anxiety disorders in chronic daily headache and its subtypes. Headache 40:818-823.
19. Korff von M, Wagner EH, Saunders K (1992). A chronic disease score from automated pharmacy data. J Clin Epidemiol 45:197-203.
20. Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF (2000). Migraine, quality of life, and depression: a population based case-control study. Neurology 55:629-635.
21. Mattsson P, Ekselius L (2002). Migraine, major depression, panic disorder, and personality traits in women aged 40-74 years: a population-based study. Cephalagia 22:543-551.
22. Merikangas KR, Angst J, Isler H (1990). Migraine and psychopathology. Results of the Zurich cohort study of young adults. Arch Gen Psychiatry 41: 849-853.
23. Millson D, Frischer M, Croft P, Goadsby PJ (2000). Are triptans with enhanced lipophilicity used for the acute treatment of migraine associated with an increased consulting rate for depressive illness? Cephalalgia 20:732-737.
24. Mitsikostas DD, Thomas AM (1999). Comorbidity of headache and depressive disorders. Cephalalgia 19:211-217.
25. Peroutka SJ, Price SC, Wilhoit, Jones KW (1998). Comorbid migraine with aura anxiety, and depression is associated with dopamine D2 receptor Ncol alleles. Mol Med 4:14-21.
26. Petri H, de Vet CW, Naus J, et al. (1988). Prescription sequence analysis: a new and fast method for assessing certain adverse reactions of prescription drugs in large populations. Stat Med 7:1171-1175.
27. Putnam GP, O'Quinn S, Bolden-Watson CP, Davis RL, Gutterman DL, Fox AW (1999). Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study. Cephalalgia 19:668-675.
28. Radat F, Sakh D, Lutz G, el Amrani M, Ferreri M, Bousser MG (1999). Psychiatric comorbidity is related to headache induced by chronic substance use in migraineurs. Headache 39:477-480.
29. Rahimtoola H, Buurma H, Tijssen CC, Leufkens HG, Egberts ACG (2002). Incidence and determinants of migraine prophylactic medication in The Netherlands. Eur J Clin Pharmacol 58:149-155.
30. Rahimtoola H, Buurma H, Tijssen CC, Leufkens HG, Egberts ACG (2003). Single use of sumatriptan - a patient interview study. Headache 43: 109-116.
31. Rouillon F, Blachier C, Dreyfus JP, Bouhassira M, Allicar MP (1996). Pharmacoepidemiologic study of antidepressant drugs in the general population. Encephale 1:39-48.
32. Silberstein SD, Goadsby PJ (2002). Migraine: preventive treatment. Cephalalgia 22:491-512.
33. Stewart W, Breslau N, Keck PE (1994). Comorbidity of migraine and panic disorder. Neurology 44(suppl 7):23-27.
34. Swartz K, Pratt L, Haroutune K, Ching L, Eaton W (2000). Mental disorders and the incidence of migraine headaches in a community sample. Arch Gen Psych 157:1-17.
35. Tomkins GE, Jackson JL, O'Malley PG, Balden E, Santoro JE (2001). Treatment of chronic headache with antidepressants: a meta-analysis. Am J Med 111:54-63.
36. Tonon C, Guttmann S, Volpini M, Naccarato S, Cortelli P, D'Alessandro R (2002). Prevalence and incidence of cluster headache in the Republic of San Marino. Neurology 58:1407-1409.
37. von Korff M, Black LK, Saunders K, Galer BS (1999). Headache medication use among primary care headache patients in a health maintenance organization. Cephalalgia 19:575-580.